1. Not all stage I and II endometrial cancers are created equal: Recurrence-free survival and cause-specific survival after observation or vaginal brachytherapy alone in all subgroups of early-stage high-intermediate and high-risk endometrial cancer.
- Author
-
Garzon, Simone, Grassi, Tommaso, Mariani, Andrea, Kollikonda, Swapna, Weaver, Amy L., McGree, Michaela E., Petersen, Ivy A., Weroha, S. John, Glaser, Gretchen E., Langstraat, Carrie L., Amarnath, Sudha R., and AlHilli, Mariam M.
- Subjects
- *
ENDOMETRIAL cancer , *RADIOISOTOPE brachytherapy , *CONFIDENCE intervals , *SURGICAL clinics , *OVERTREATMENT of cancer , *ENDOMETRIAL surgery , *ENDOMETRIAL hyperplasia - Abstract
To evaluate recurrence-free survival (RFS) and cause-specific survival (CSS) after observation or vaginal brachytherapy (VB) alone in all subgroups of early-stage high-intermediate (HIR) and high-risk endometrial cancer (EC). We identified patients with stage I HIR (GOG-249 criteria) and stage II endometrioid EC, and stage I and II non-endometrioid EC who underwent surgery at Mayo Clinic and Cleveland Clinic between 1999 and 2016. Three-year RFS and CSS after observation or VB only were estimated in 16 subgroups defined by risk factors. Among 4156 ECs, we identified 447 (10.8%) stage I endometrioid HIR, 52 (1.3%) stage II endometrioid, 350 (8.4%) stage I non-endometrioid, and 17 (0.4%) stage II non-endometrioid ECs; observation or VB alone was applied in 349 (78.1%), 24 (46.2%), 187 (53.4%), and 2 (11.8%) patients, respectively. After observation or VB, stage I HIR endometrioid EC subgroups with <2 factors among grade 3, LVSI, or stage IB had a 3-year CSS >95% (lower 95% confidence intervals limit: 89.8%), whereas subgroups with ≥2 factors had poorer outcomes. No EC-related deaths after 3 years were reported in 97 stage IA non-endometrioid ECs without myometrial invasion. Stage II ECs had poor outcomes regardless of histology. Observation or VB only may be sufficient in stage I endometrioid HIR ECs with <2 factors among grade 3, LVSI, or IB and in stage IA non-endometrioid ECs without myometrial invasion. Stratification of early-stage HIR and high-risk ECs into risk subgroups potentially alleviates the overtreatment and undertreatment risk and should be considered in future research. • Some subgroups of high-intermediate-risk and high-risk endometrial cancer (EC) represent <1% of all ECs. • Three-year cause-specific survival after observation or brachytherapy only is higher than 85% in 15 of the 16 subgroups. • Observation or brachytherapy may be adequate in stage I endometrioid ECs without grade 3 or lymphovascular space invasion. • Non-endometrioid ECs without myometrial invasion have a good prognosis with only observation or vaginal brachytherapy. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF